In a recent discussion, Dr. Owen O’Connor and Dr. Zhengzi Qian addressed the complexities of peripheral T-cell lymphoma (PTCL) and shared insights on new therapeutic strategies. They highlighted the diversity of PTCL subtypes and the promising role of novel drugs, such as PI3K inhibitors and EZH2 inhibitors, in improving outcomes. The conversation also emphasized the importance of early combination therapies over traditional chemotherapy and the future potential of chemotherapy-free regimens.

In a recent interview, Dr. Lanfang Li and Professor Zhuang Weiyun from the University of California, San Francisco discussed breakthroughs in treating Mycosis Fungoides (MF) and Sézary Syndrome (SS), focusing on the efficacy of brentuximab vedotin and mogamulizumab. They highlighted the importance of targeting different disease compartments and leveraging new drugs to improve patient outcomes. With advancements in targeted therapies and an emphasis on early diagnosis, the experts emphasized the need for multidisciplinary collaboration to better manage these rare but challenging conditions.

From September 25-29, 2024, the "27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting," hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. With the theme "Patient-Centered, Sharing the Future," the conference will showcase major research advancements and developments in the field both domestically and internationally. Over the past 20 years, CSCO has continuously led the development of clinical oncology in China, with many experts deeply involved in its growth, advancing their careers through this platform. Hematology Frontier has launched a special "Growing with CSCO" series in response to CSCO's call, inviting Chinese scholars to revisit past stories. In this issue, we have invited Dr. Jun Ma, Chairman of the Supervisory Board of CSCO and Director of the Harbin Institute of Hematology and Oncology, to share his touching stories of "growing with CSCO."